Fennec Pharmaceuticals Inc.: CEO Jeffrey S. Hackman received 2,224 shares

What happened The filing says Jeffrey S. Hackman, chief executive officer, received 2,224 common shares as an award/acquisition on Oct 12, 2026 at $5.53 per share, for $12,299.

Key details

• Transaction date and price: Oct 12, 2026 — 2,224 shares at $5.53 per share.
• Transaction type: Grant/award or other acquisition (code A).
• Shares owned after the transaction: the filing does not report post-transaction holdings.
• Footnotes: F1 — shares were acquired under the Fennec Pharmaceuticals Inc. employee stock purchase plan (ESPP) for the purchase period Apr 9, 2026 through Oct 12, 2026; F2 — shares were purchased at 85% of the closing price on the Nasdaq Capital Market on Apr 9, 2026.
• Form 4 filed on Oct 13, 2026 for the Oct 12, 2026 transaction.

Why it may matter The filing shows an ESPP purchase under the company plan, which is not a market trade. A filing does not show why the insider traded or why the company acted.